FDA approves pancreatic cancer drug that extends patients’ lives
In trials, Revolution Medicines’ daraxonrasib nearly doubled average survival times for one of the deadliest cancers.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.washingtonpost.com — the content belongs to The Washington Post.
